From the team at Monarch Bay Optometry | Dana Point, California
You’ve seen the commercials. You’ve heard the conversations at the gym, at dinner, maybe even at your last doctor’s appointment. Ozempic. Wegovy. Mounjaro. These medications are everywhere right now, and for good reason.
But here’s a question most people never think to ask: What do these drugs mean for your eyes?
As your local Dana Point eye doctors, we want to give you the real story, the good, the not-so-good, and what it means for your next eye exam.
First, Let’s Talk About Why These Drugs Are Kind of a Big Deal
GLP-1 medications (the category that includes Ozempic, Wegovy, Mounjaro, and others) were originally developed to help manage type 2 diabetes. But researchers quickly realized they do a lot more than just lower blood sugar.
Here’s what the science shows these medications can do for your overall health:
| What They Help With | Why It Matters |
| Blood sugar control | Without the dangerous blood sugar crashes of older diabetes drugs |
| Weight loss | Among the most effective non-surgical options ever developed |
| Heart health | Studies show fewer heart attacks and strokes |
| Kidney protection | Can slow down kidney disease progression |
| Brain health | Early research suggests possible protection against Alzheimer’s and Parkinson’s |
| Inflammation | Help calm down inflammation throughout the entire body |
These aren’t small wins. For millions of people managing diabetes, obesity, or heart disease, these medications are genuinely life-changing.
So… What Does This Have to Do With My Eyes?
Here’s where it gets really interesting — and where your eye doctor becomes an important part of your healthcare team.
🟢 The Surprisingly Good News for Your Eyes
Researchers are finding that GLP-1 medications may actually protect your eyes in several ways:
Glaucoma — You May Have Less Risk
Glaucoma is a sneaky condition where pressure builds up in the eye and slowly damages your vision — often without any warning signs. A large study found that people taking GLP-1 medications had up to 50% lower risk of developing glaucoma compared to people on other diabetes medications. Scientists think these drugs help protect the delicate nerve cells in the back of your eye.
Diabetic Eye Disease — A Protective Effect Over Time
If you have diabetes, you’ve probably heard about diabetic retinopathy — damage to the tiny blood vessels in your retina. Compared to insulin, people on GLP-1 medications had a 34% lower risk of developing diabetic retinopathy. These drugs also help stabilize the blood vessels in your eye and reduce harmful inflammation.
Cataracts — Possibly Fewer, Later in Life
A large database study found that people taking semaglutide (Ozempic/Wegovy) or liraglutide had significantly lower rates of age-related cataracts — even when tracked over 5, 7, and 10 years.
Macular Degeneration — Early Signs Are Encouraging
The same research found lower rates of dry macular degeneration (the most common form of AMD, which affects your central vision) among GLP-1 users.
Eye Inflammation (Uveitis) — About Half the Risk
New data presented at a major eye conference found that GLP-1 users had roughly half the risk of developing uveitis — a painful inflammation inside the eye — compared to people not on these medications. This held true even for people without diabetes.
🟡 The Things We Watch Out For
We’d be doing you a disservice if we only told you the good stuff. Here’s what we keep an eye on (pun intended):
- Early Worsening of Diabetic Eye Disease
This one surprises people. When blood sugar drops quickly — which these medications can cause — the blood vessels in your retina can temporarily become unstable. Studies show a possible 31% increased risk of early-stage diabetic retinopathy in the short term.
Think of it like this: if your blood sugar has been high for years, your blood vessels have adapted to that environment. When things change rapidly, there can be a temporary adjustment period. This is why more frequent eye exams during the first year of treatment are so important for diabetic patients.
- A Rare but Serious Concern: Sudden Vision Changes
There have been reports, particularly with semaglutide (Ozempic/Wegovy), of a condition called NAION, which involves sudden vision loss due to reduced blood flow to the optic nerve. This is still being studied, and it appears to be rare, but it’s something we take seriously. If you ever experience sudden vision changes while on these medications, call us immediately.
- Everyday Side Effects That Can Affect Your Eyes
The most common side effects of GLP-1 drugs are nausea and stomach upset, affecting up to 40% of users. 9 Dehydration from these symptoms can affect your tear film and contribute to dry eye symptoms. Some patients also notice changes around their eyes as they lose significant weight (sometimes called “Ozempic face”), which can affect eyelid position and comfort.
What Should You Actually Do?
Here’s the practical takeaway, no medical jargon required:
The Bottom Line (In Plain English)
GLP-1 medications like Ozempic and Mounjaro are genuinely impressive drugs. The benefits for your heart, metabolism, kidneys, and even your brain are well-documented and significant.
The eye health story is mostly encouraging too, with real potential to protect against glaucoma, cataracts, macular degeneration, and eye inflammation.
But, and this is important, these are powerful medications that deserve careful monitoring. The risks are real, especially for people with existing diabetic eye disease. The answer isn’t to avoid these medications out of fear. The answer is to make sure your eye care is part of your overall health picture.
That’s exactly what we’re here for.
At Monarch Bay Optometry, we believe your eyes are a window into your whole-body health. Whether you’re on a GLP-1 medication, thinking about starting one, or just want to make sure your eyes are in great shape, we’re your partners in that journey.
📍 Monarch Bay Optometry | Dana Point, California
Ready to schedule your comprehensive eye exam? Give us a call! 949-487-3937
Your eyes will thank you.
Sources include peer-reviewed research published in Survey of Ophthalmology, Clinical & Experimental Ophthalmology, Frontiers in Pharmacology, the New England Journal of Medicine, and clinical reporting from Healio Ophthalmology & Optometry
Selected References:
Kapoor et al., Survey of Ophthalmology, 2023 | Kapoor et al., Clinical & Experimental Ophthalmology, 2024 | Zhou et al., Frontiers in Pharmacology, 2021 | Thomsen et al., Diabetes, Obesity & Metabolism, 2025 | Albanese et al., Diabetology, 2025 | Xie et al., Frontiers in Pharmacology, 2025 | Rosen & Ingelfinger, NEJM, 2026 | Ma et al., Int J Biol Sci, 2021 | Healio/Cureus Review, 2026 | Healio/*AJO* & JAMA Ophthalmology, 2025 | Sunshine Eye & Retina 2026 Conference
